• Organization: U.S. Department of Health & Human Services
• Updated: 2025-09-06

Background Numerous agencies have developed clinical practice guidelines for the management of postmenopausal osteoporosis. The study objective was to conduct a systematic assessment of...

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-09-06

Background Bisphosphonates are indicated in the prevention and treatment of osteoporosis. However, bone mineral density (BMD) continues to decline in up to 15% of bisphosphonate users....

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-09-06

Background The identification of new methods of evaluating patients with osteoporotic fracture should focus on their usefulness in clinical situations such that they are easily measured...

• html

• Organization: National Aeronautics and Space Administration
• Updated: 2025-04-23

Prolonged skeletal unloading through bedrest results in bone loss similar to that observed in elderly osteoporotic patients but with an accelerated timeframe. This rapid effect on weight-bearing...

• html

• Organization: National Aeronautics and Space Administration
• Updated: 2025-04-23

Prolonged skeletal unloading through bedrest results in bone loss similar to that observed in elderly osteoporotic patients but with an accelerated timeframe. This rapid effect on weight-bearing...

• html

• Organization: National Aeronautics and Space Administration
• Updated: 2025-04-23

Prolonged skeletal unloading through bedrest results in bone loss similar to that observed in elderly osteoporotic patients but with an accelerated timeframe. This rapid effect on weight-bearing...

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-09-06

Background Little empirical research has examined the multiple consequences of osteoporosis on quality of life. Methods Health related quality of...

• html

• Organization: National Aeronautics and Space Administration
• Updated: 2025-04-23

Physical inactivity decreases the mechanical load on the skeleton which when prolonged leads to losses of muscle strength and bone mass in humans and most mammalian species. Hibernating mammals...

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-09-06

Inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase enzyme have recently been shown to stimulate bone formation in rodents both in vitro and in vivo. In bone cells, these inhibitors...

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-09-06

Osteoarthritis and osteoporosis are the two most common age-related chronic disorders of articular joints and skeleton, representing a major public health problem in most developed countries....

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-09-06

Rheumatoid arthritis represents an excellent model in which to gain insights into the local and systemic effects of joint inflammation on skeletal tissues. Three forms of bone disease have...

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-09-06

Osteoporosis (OP) and osteoarthritis (OA), the two most common age-related chronic disorders of articular joints and skeleton, represent a major public health problem in most developed countries....

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-03-17

Calcitonin Salmon is a prescription nasal spray containing 200 IU of calcitonin salmon per metered dose. It belongs to the calcitonin class and is used to treat osteoporosis in postmenopausal...

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-03-17

Ibandronate Sodium is a prescription injectable medication used to treat bone disorders like osteoporosis. It belongs to the bisphosphonate class and is administered intravenously. This generic...

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-03-17

Bonsity (teriparatide) is a prescription injection used to treat osteoporosis in certain patients by helping build stronger bones. It's administered subcutaneously as a solution containing 250...

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-09-06

Backgroud Bone mineral density (BMD) is a marker of long-term estrogen exposure. BMD measurement has been used in this context to investigate the association of estrogen with breast...

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-03-17

Risedronate Sodium is a generic bisphosphonate medication used to treat and prevent osteoporosis by strengthening bones. It comes as a 35 mg delayed-release oral tablet, manufactured by Sun...

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-03-17

Zoledronic Acid is a generic prescription drug manufactured by Hikma Pharmaceuticals USA Inc., available as an intravenous injection (4 mg/5 mL concentrate). It's a bisphosphonate used to treat...

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2025-03-17

Yorvipath (palopegteriparatide) is a prescription medication injected under the skin to treat osteoporosis in certain adults. It works by mimicking parathyroid hormone to help build bone strength....

• html

• Organization: U.S. Department of Health & Human Services
• Updated: 2023-07-26

The Nuclear Receptor Signaling Atlas (NURSA) is designed to foster the development of a comprehensive understanding of the structure, function, and role in disease of nuclear receptors (NRs) and...